- Home
- Media Center
- Press releases
- Innovative Medicine
Innovative Medicine
TREMFYA® (guselkumab) Maintains Key Efficacy Endpoints Through Three Years for Adults with Moderately to Severely Active Crohn’s Disease in a Phase 2 Study
Key efficacy endpoints of the long-term extension GALAXI study included clinical remission, patient-reported outcome remission, and endoscopic response
Janssen to Highlight Latest Research from Nipocalimab Clinical Development Program to Address Unmet Need in Myasthenia Gravis at AANEM 2023 Meeting
Data presentations reinforce potential for rapid, deep, and sustained efficacy with treatment and demonstrate how the unique immuno-selectivity of the compound may allow for greater targeting across a wide range of autoantibody-driven diseases
Janssen Aims to Define New Standards of Care in the Treatment of Solid Tumor Cancers with Transformative Data Planned for Presentation at ESMO
Three Phase 3 RYBREVANT® (amivantamab-vmjw) studies (MARIPOSA, MARIPOSA-2 and PAPILLON) in EGFR-mutated lung cancer achieved statistically significant and clinically meaningful progression-free survival endpoints and will be presented in Presidential Symposium sessions New results for investigational TAR-200 and TAR-210 novel intravesical delivery system highlight potential for transformational outcomes in the treatment of bladder cancer
Janssen Highlights Latest Research for TREMFYA® (guselkumab) and Investigational Targeted Oral Peptide JNJ-2113 in Moderate to Severe Plaque Psoriasis at the European Academy of Dermatology and Venereology (EADV) Congress
30 presentations showcase breadth of data from Janssen’s Immunodermatology pipeline across five commercialized and investigational therapies
Janssen Submits Application to the European Medicines Agency for RYBREVANT®▼ (amivantamab) in Combination with Chemotherapy for the First-Line Treatment of Adult Patients with Advanced Non-Small Cell Lung Cancer with Activating EGFR Exon 20 Insertion Mutations
Type II Extension of Indication Application is supported by data from PAPILLON, the first randomised Phase 3 study to read out in patients with NSCLC with EGFR exon 20 insertion mutations1
SPRAVATO® (esketamine) Demonstrates Superior Efficacy Compared to Quetiapine Extended-Release in Treatment-Resistant Major Depressive Disorder
Data Published in the Current Issue of New England Journal of Medicine.
Janssen to Highlight Latest Advances in Retina Portfolio at the European Society of Retina Specialists (EURETINA) 2023 Annual Meeting
Five abstracts to be presented, including new real-world research and data on Janssen’s investigational gene therapy JNJ-1887
Janssen Enters into Agreement with Sanofi to Advance Potential First-In-Class Vaccine Program
Vaccine candidate is being evaluated in Phase 3 study for the prevention of invasive E. coli disease (IED) which affects nearly 10 million adults annually1
Johnson & Johnson Confirms Intent Not to Enforce Patents for SIRTURO® (bedaquiline) for the Treatment of Multidrug-Resistant Tuberculosis in 134 Low- and Middle-Income Countries
Company continues to be focused on addressing perceived barriers to access and refocusing global efforts on the most-pressing barrier to access: underdiagnosis of the disease. Decision builds on a decade of Company investments in collaborative efforts to help countries sustainably scale up access and bring people living with multidrug-resistant tuberculosis (MDR-TB) into treatment.